Francesco Granata

Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016.

Italfarmaco SpA engages in the production and distribution of pharmaceutical and fine chemical products. It also provides research and development, scientific publishing, business development, and licensing services. The company was founded in 1938 and is headquartered in Milan, Italy.

Quanta Dialysis Technologies Ltd. develops haemodialysis systems. The firm's SC+ is a performance, portable, compact haemodialysis system providing clinical efficacy utilising flow rates typically used on traditional machines. It offers SelfCare+, a haemodialysis machine for dialysis patients to control their disease and determine the treatment regime and care. The company was founded by Clive Henrey Buckberry, John Eric Milad and Martin Johnson in 2008 and is headquartered in Alcester, the United Kingdom.

Helsinn Holding SA is a holding Swiss company that provides cancer services through its subsidiaries. The private company is based in Lugano, Switzerland and has subsidiaries in Switzerland and Ireland. The company was founded in 1976 by Gabriele Edoardo Braglia. Riccardo Braglia has been the CEO of the company since 2002.

BSP Pharmaceuticals SpA develops and manufactures anticancer drugs. It offers development, clinical supply, commercial supply, and analytical services. The company was founded by Aldo Braca in July 2006 and is headquartered in Latina Scalo, Italy.

Prismic Pharmaceuticals, Inc. engages in the research and development of prescription drugs for kidney disease, mental health, and chronic pain. It also offers medical foods for patients with chronic kidney disease, and depression and bipolar disorder. The company was founded by Zachary Dutton, Danilo Casadei Massari, and Peter J. Moriarty in 2011 and is headquartered in Worcester, MA.

Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom.

Helsinn Healthcare SA /Venture/ is a Venture Capital firm, a subsidiary of Helsinn Healthcare SA founded in 1992. Helsinn Healthcare SA /Venture/ is headquartered in Luxembourg.

FSI SGR SpA (FSI) also known as Fondo Strategico Italiano, is an independent private equity firm. The firm was founded in 2016 and is headquartered in Milan, Italy.

Micromega Ltd. provides business support services. The private company is based in London, UK. The British company was founded by Francesco Granata.

Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections.

Diadem Srl predicts, monitors, diagnosis and drug development for Alzheimer?s disease. focuses on specific research on early peripheral markers of Alzheimer's disease into technology. The company was founded by Maurizio Memo and Daniela Uberti in June 2012 and is headquartered in Brescia, Italy.